Pulmonary Near-infrared Spectroscopy to Predict the Need for Surfactant in Very Low Birth Weight Infants (PNIRS in VLBWI)

November 17, 2026 updated by: Lizelle Van Wyk, University of Stellenbosch

Pulmonary Near-infrared Spectroscopy to Predict the Need for Surfactant in Very Low Birth Weight Infants: a Pilot Study

This study will look at whether a monitoring method called near-infrared spectroscopy (NIRS), can help assess lung disease in premature babies.

The main aim of this study is to describe lung oxygen levels measured by NIRS in premature babies with respiratory distress syndrome (RDS) during the first 72 hours after birth. The study will include babies born at or before 32 weeks of pregnancy who need continuous positive airway pressure (CPAP) for RDS. The study will also assess whether these lung oxygen measurements can help predict which babies will need surfactant treatment, and whether they can predict which babies may need more than one dose of surfactant.

The study will also compare lung NIRS measurements with other ways of assessing breathing problems, including lung ultrasound scores and oxygen-related measurements. In addition, the researchers will compare lung oxygen measurements with brain oxygen measurements. They will also look at whether surfactant treatment changes oxygen levels in the lungs and brain. Information from routine vital signs, such as heart rate, breathing rate, and oxygen saturation, will also be studied to see whether these measurements can help predict the need for surfactant.

Added to this researchers will look at the hemodynamics of surfactant administration by seeing how the heart and blood vessels react to surfactant administration

Study Overview

Status

Recruiting

Detailed Description

Aim: To determine pulmonary regional oxygen saturation (prSO2) in preterm infants (≤32 weeks) with respiratory distress syndrome (RDS) requiring continuous positive airway pressure (CPAP) with or without surfactant replacement therapy (SRT)

Objectives:

Primary: Determine longitudinal prSO2 values for infants with RDS during first 72 hours of life. Secondary: (1) Evaluate the ability of prSO2 to predict the need for surfactant administration in preterm infants with RDS, (2) Evaluate the ability of prSO2 to predict the need for repeat surfactant administration in preterm infants with RDS, (3) Determine correlation between prSO2, lung ultrasound (LUS) scores and oxygenation indices.

Tertiary: (1) Determine the correlation between prSO2 and cerebral oxygenation (crSO2), (2) Determine the effect of surfactant administration on prSO2 and crSO2, (3) longitudinal analyses of vital signs (HR, SpO2, NIRS, oxygenation indices) to predict SRT, (4) determine the hemodynamic effects of SRT (longitudinal correlation of NIRS, haemodynamic parameters)

This will be an investigator-initiated, prospective, observational trial.

Preterm infants born at a gestational age ≤ 32 weeks will be recruited from a single neonatal center, Tygerberg Hospital, Cape Town, South Africa.

All preterm infants ≤ 32 weeks and/ or ≤1800g will be eligible for enrollment

Study Procedures

Recruitment and enrollment processes Infants will be screened within the first 3 hours after birth. Infants meeting enrollment criteria will be placed on study monitoring devices upon arrival in the neonatal unit, if meeting eligibility criteria.

Randomization/ blinding No randomization will occur in this study. Blinding is not possible due to visible monitoring equipment. Treating clinicians will however be directed not to use the monitors for any decision-making regarding patient management.

Monitoring Devices

  1. Near-infrared spectroscopy will be performed using INVOS 5100c (Medtronics, Minneapolis, MN, USA) with 2 transducers, will be used that allows monitoring of 4 regions of interest. In this study 3 regional saturations will be monitored - pulmonary (left and right) and cerebral

    • Pulmonary NIRS - Pulmonary sensors will be placed in a horizontal position at the 4th intercostal space area (nipple line) on the left and right hemithorax
    • Cerebral NIRS - Cerebral sensor will be placed on the right of the forehead
  2. Vital sign monitoring: Synchronized vital signs (heart rate (HR), respiratory rate (RR), peripheral oxygen saturation (SpO2) (Nellcor) will be monitored using a multi-parameter monitor (Mindray UMEC15, Shenzhen, China).

  3. Non-invasive cardiac output monitoring: Haemodynamic monitoring will occur using the ICON Core from Osypka Medical. This provides non-invasive monitoring of numerous haemodynamic parameters, including cardiac output, stroke volume, systemic vascular resistance, cardiac contractility and thoracic fluid content. ICON sensors will be placed in standard positions on the forehead, neck arm and leg for monitoring.

Intervention procedures

1. Ultrasound:

  1. Lung ultrasound (LUS) will be performed after placement of the NIRS (within the first 6 hours of life) and daily. LUS will also be performed prior to any SRT. alculated. Video-clips will be stored and reviewed by blinded co-investigators.
  2. Cranial ultrasound (CUS) will be performed on day 1,2 and 3 to monitor for any intraventricular haemorrhage as well as to measure cerebral blood flow velocities, which may affect crSO2 values.
  3. Point-of-care echocardiography (POC-echo) will be performed to determine cardiac function, cardiac output, and the presence of a patent ductus arteriosus, size, flow velocity and pattern, which may affect prSO2 and crSO2 values. Standard echocardiography techniques will be used and will be performed daily on day 1,2 and 3 of life.

Trial duration

The trial will start enrolling 1 November 2026 or when all procedures have been completed. Trial will be completed when 100 participants have been recruited.

Discontinuation of study intervention

Monitoring of the infant will stop, and sensors will be removed if:

  • Requested by mother
  • Requested by treating clinician
  • Thoracic intervention required (e.g. intercostal drainage for pneumothorax)
  • Surgery required (e.g. laparotomy for focal intestinal perforation)
  • Sensors interfere with medical management

Withdrawal from study

At any time point the mother or treating clinician may request withdrawal of the infant from the study, for any reason, whether for personal choice (by the mother), safety considerations or administrative reasons. Monitoring of the infant will be stopped immediately, and no further data will be collected. However, the infant will remain in the study for data analyses and outcome and clinical measure collection, unless the mother specifically requests that their infant's data not be included. Withdrawal of the infant from the study, irrespective of reason, will not influence the continued management of the infant and they will continue to receive management as per protocols in the institution.

Duration of study participation

Study participation for each infant is:

  • Initiated within the first 3 hours of life
  • Monitoring until 72 hours after birth
  • Follow up from 72 hours until final discharge from hospital or in-hospital death.

Infants who are transferred to other institutions will be followed up for length of stay as well as neonatal respiratory complications (length of respiratory support, bronchopulmonary dysplasia, death)

Study Type

Observational

Enrollment (Estimated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Cape Town, South Africa, 7530
        • Recruiting
        • Tygerberg Hospital
        • Contact:
        • Contact:
        • Principal Investigator:
          • Lizelle Van Wyk, PhD
        • Sub-Investigator:
          • Pierre Goussard, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

6 months to 7 months (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

All preterm infants 27-32 weeks born at Tygerberg Hospital, Cape Town, South Africa will be elligible for enrollment

Description

Inclusion Criteria:

  • Preterm infant ≤ 32 weeks gestational age and/ or birth weight ≤ 1800g
  • Infant diagnosed with respiratory distress syndrome requiring CPAP after birth
  • Infant born at the research institution

Exclusion Criteria:

  • Infants ≤ 26 weeks gestational age or <750g
  • Infants with other causes of respiratory distress
  • Infants with antenatal or postnatally diagnosed structural pulmonary abnormalities
  • Infants with known or suspected chromosomal abnormalities
  • Infants with other congenital structural abnormalities that may require surgery in the first 72 hours after birth
  • Infants with known or suspected congenital infections including congenital syphilis, cytomegalovirus or toxoplasmosis
  • Infants intubated after birth or requiring intubation and invasive ventilation immediately after birth
  • Infants with a 5-minute Apgar ≤ 5
  • Instillation of surfactant prior to enrollment
  • Infants not expected to survive the first 72 hours after birth

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: PROSPECTIVE

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
CPAP only

Infants receiving CPAP only

Pulmonary near-infrared spectroscopy sensors will be placed in a horizontal position

SRT

Infants receiving CPAP plus surfactant

Pulmonary near-infrared spectroscopy sensors will be placed in a horizontal position

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
PRSO2 values
Time Frame: 72 hours

Determine longitudinal prSO2 values for infants with RDS during first 72 hours of life

72 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
SRT prediction
Time Frame: 72 hours

Evaluate the ability of prSO2 to predict the need for surfactant administration in preterm infants with RDS

72 hours
Compare prSo2 & lung ultrasound between groups
Time Frame: 72 hours

Determine correlation between prSO2 and lung ultrasound (LUS) scores between groups

72 hours
Compare prSo2 & OSI between groups
Time Frame: 72 hours

Determine correlation between prSO2 and OSI between groups

72 hours
Compare prSo2 & SOPI between groups
Time Frame: 72hrs

Determine correlation between prSO2 and SOPI between groups

72hrs

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
PRSO2/CUS
Time Frame: 72hours

Determine the correlation between prSO2 and cerebral oxygenation (crSO2) between groups

72hours
Longitudinal analysis SOPI
Time Frame: 72 hours

longitudinal comparison of SOPI between groups

72 hours
Longitudinal OSI
Time Frame: 72 hours

longitudinal comparison of OSI between groups

72 hours
Longitudinal thoracic fluid content (TFC)
Time Frame: 72 hours

longitudinal comparison of TFC between groups

72 hours
Longitudinal CI
Time Frame: 72 hours

longitudinal comparison of cardiac index between groups

72 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2026

Primary Completion (Estimated)

December 30, 2027

Study Completion (Estimated)

December 31, 2027

Study Registration Dates

First Submitted

May 13, 2026

First Submitted That Met QC Criteria

November 17, 2026

First Posted (Actual)

November 20, 2026

Study Record Updates

Last Update Posted (Actual)

November 20, 2026

Last Update Submitted That Met QC Criteria

November 17, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Patient data, as per SUN HREC guidelines, can only be shared upon an agreed upon data sharing agreement

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe